Express Mail Label No.	Dated:	

Docket No.: 20052/1200522-US1

(PATENT)

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Randolph J. Noelle et al.

Application No.: 09/835,126

Confirmation No.: 4674

Filed: April 16, 2001

Art Unit: 1644

For: EX VIVO TREATMENT OF ALLOGENEIC

AND XENOGENEIC DONOR T-CELLS CONTAINING COMPOSITIONS (BONE MARROW) USING gp39 ANTAGONISTS

AND USE THEREOF

Examiner: P. Gambel

### **INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of each document on the PTO/SB/08 is attached.

02/09/2004 TBESHAH1 00000019 09835126

01 FC:1806

180.00 OP



**H** 

Application No.: 09/835,126 2 Docket No.: 20052/1200522-US1

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: February 2, 2004

Respectfully submitted,

Anna Lövqvist, Ph.D

Limited Recognition Under 37 C.F.R. 10.9(b) (see attached)

Representative of Applicants

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

7. Jan 1

Smogl

02-04-04



Application No. (if known): 09/835,126

Attorney Docket No.: 20052/1200522-US1



## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No.

EL994068998-US

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on February 2, 2004

Date

Signature Signature D. Navis

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Certificate of Express Mailing (1 page)

Fee Transmittal (1 page)

Check No. 4046 in the amount of \$180.00 Information Disclosure Statement (2 pages)

Limited Recognition under 37 C.F.R. 10.9(b) (1 page)

Supplementary European Search Report dated 01/28/03 (4 pages)

Form PTO/SB/08 (1 page)

Six (6) References

Return Receipt Postcard.

PTO/SB/17 (10-03)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

09/835,126

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

		4	for	FY 2004	1	L	Filing	Date		April 16, 2001		
OIPE							First I	Named	Inver	ntor Randolph J. Noelle	Randolph J. Noelle	
/	Eff	ective 10/t	01/2003, Pa	atent fees are subject to an	nual revision. 	[	Exam	iner Na	ıme	P. Gambel		
(C) (C)		pplicant	claims sn	nall entity status. See 3	37 CFR 1.27	ľ	Art Unit			1644		
FEB 0 2 2004	TOTAL	AMOUN	T OF P	AYMENT (\$)	180.00		Attom	ey Doo	ket No	o. 20052/1200522-US1		
	METHOD OF PAYMENT (check all that apply)							FEE	CALCULATION (continued)			
FEB 0 2 2004	X Check Card Money Order Other None				3. A	DDITIO	ONAL		<del></del>			
AUE III	Dep	osit Acco	unt:						_			
	Deposit Account		(	04-0100		Fee	Fee	Fee	Fee	- Fee Description		
	Number	<u>L</u>				Code	(\$)	Code	(\$)	F	ee Paid	
	Deposit Account		Darby	& Darby P.C.		1051	130	2051	65	Surcharge – late filing fee or oath		
	Name The Direct	or is auth	norized to	: (check all that apply)		1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.		
	Charg	ge fee(s) in	dicated be	low X Credit any o	overpayments	1053	130	1053	130	Non-English specification		
	Char	ge any add	litional fee(	s) or any underpayment of	fee(s)	1812	2,520	1812	2,520	For filing a request for ex parte reexamination		
	Charg	ge fee(s) ir	ndicated be	low, except for the filing f	·ee	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action		
	to the above-identified deposit account.			1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action				
			FEE CA	ALCULATION		1251	110	2251	55 <sup>:</sup>	· -		
	1. BASI	FILING	G FEE	,		1252	420	2252	210	Extension for reply within second month		
	Large Enti	· 1	II Entity			1253	950	2253	475	Extension for reply within third month		
	Fee Fe Code (\$		(\$)	Fee Description	Fee Paid	1254	1,480	2254	740	Extension for reply within fourth month		
	1001 77	0 2001	385	Utility filing fee		1255	2,010	2255	1,005	Extension for reply within fifth month		
	1002 34	2002	170	Design filing fee		1401	330	2401	165	Notice of Appeal		
	1003 53	0 2003	265	Plant filing fee		1402	330	2402	165	Filing a brief in support of an appeal		
	1004 77	2004	385	Reissue filing fee		1403	290	2403	145	Request for oral hearing		
	1005 16	2005	80	Provisional filing fee		1451	1,510	1451	1,510	Petition to institute a public use proceeding		
			SUBTO	OTAL (1) (\$)	0.00	1452	110	2452	5 <b>5</b>	Petition to revive – unavoidable		
		<u> </u>		γιλε (1) [ (ψ)	0.00	1453	1,330	2453	665	Petition to revive - unintentional		
	2. EXTR	A CLAII	M FEES	FOR UTILITY AND	REISSUE	1501	1,330	2501	665	Utility issue fee (or reissue)		
				Extra Fee from Claims below	Fee Paid	1502	480	2502	240	Design issue fee		
	Total Claims	s	] -** =	x=		1503	640	2503	320	Plant issue fee		
	Independen Claims	t	j .**=	x =		1460	130	1460	130	Petitions to the Commissioner		
	Multiple De	pendent	-	=		1807	50	1807	50	Processing fee under 37 CFR 1.17(q)		
	Large Entit	y Small	Entity			1806	180	1806	180	Submission of Information Disclosure Stmt	180.00	
	Fee Fee	Fee	Fee	Eco Docariatio	_	9004	40	8004	40	Recording each patent assignment per		

FEE TRANSMITTAL

SUBMITTED BY				(Complete	(if applicable))
Name (Print/Type)	Anna Lövqvist, Ph.D.	Registration No. (Attorney/Agent)	See Limited Recognition	Telephone	(212) 836-3747
Signature	Ama Con	Not		Date	February 2, 2004

8021

1809

1810

1801

1802

0.00

40

770

770

770

900

Other fee (specify)

8021

2809

2810

2801

1802

\*Reduced by Basic Filing Fee Paid

385

900

property (times number of properties) Filing a submission after final rejection

For each additional invention to be

Request for expedited examination

Request for Continued Examination (RCE)

SUBTOTAL (3) (\$)

180.00

examined (37CFR 1.129(b))

of a design application

(37 CFR 1.129(a))

Express Mail Label No.	Dated:	

Fee Description

Independent claims in excess of 3

\*\* Reissue claims in excess of 20

and over original patent

145 Multiple dependent claim, if not paid

43 \*\* Reissue independent claims

over original patent

SUBTOTAL (2) (\$)

\*\*or number previously paid, if greater; For Reissues, see above

Claims in excess of 20

Code

1202

1201

1203

1204

1205

(\$)

18

86

290

86

18

Code

2202

2201

2203

2204

2205

(\$)

9

# BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE CUNITED STATES PATENT AND TRADEMARK OFFICE

## LIMITED RECOGNITION UNDER 37 CFR 10.9(b)

Anna Lovevistas hereby given limited recognition under 37 CFR 10.9(b) as an employee of the Darby & Darby P.C. law firm to prepare and prosecute patent applications wherein the patent applicant is the client of the Darby & Darby P.C. law firm, and the attorney or agent of record in the applications is a registered practitioner, located in the United States, who is a member of the Darby & Darby P.C. law firm. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Anna Lovevist ceases to lawfully reside in the United States, (ii) Anna Lovevist's employment with the Darby & Darby P.C. law firm ceases or is terminated, or (iii) Anna Lovevist ceases to remain or reside in the United States on an H1B1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: February 4, 2004

Harry I. Moatz

Director of Enrollment and Discipline



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449A/E	B/PTO		Complete if Known			
				Application Number	09/835,126		
11	NFORMATION	ON DIS	CLOSURE	Filing Date	April 16, 2001		
S	STATEMENT BY APPLICANT			First Named Inventor	Randolph J. Noelle		
				Art Unit	1644		
	(Use as many she ets as necessary)			Examiner Name	P. Gambel		
Sheet	1	of	1	Attorney Docket Number	20052/1200522-US1		

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	US-5,683,693	11-04-1997	Noelle et al.		

		FOREIG	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Τ <sup>6</sup>
	ВА	WO 97/34633 A1	09-25-1997			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	CA	BLAZAR et al., 39 <sup>th</sup> Annual Meeting of the American Society of Hematology, 1997, Abstract				
	СВ	BLAZAR et al., J. Clin. Invest. 1998;102(3):473-482				
	CC	GRIBBEN et al., Blood 1996;87(11):4887-4893				
	CD	MURPHY et al., Curr. Op. Immunol. 1999;11:509-515				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.